|
|
TrialNet Rituximab Trial
Updated May 10, 2007
If you have been diagnosed with type 1 diabetes within the last 2 months, you may be eligible to take part in a new trial testing whether treatment with a drug called Rituximab can stop or delay the destruction of insulin-producing beta cells. The trial is part of the Type 1 Diabetes TrialNet research program being conducted by doctors and scientists in the USA, Canada, Europe and UK and Australia. TrialNet research is funded by US government organizations and the Juvenile Diabetes Research Foundation.
Click here to read more about the Rituximab Trial, or follow one of the links below to learn about specific aspects of the trial.
The Rituximab Trial is supported by Type 1 Diabetes TrialNet (click on icon below to learn more about TrialNet)
Return to Clinical Trials Menu
|
